Glucotrack is a pre-revenue medical device company developing an implantable continuous blood glucose monitor (CBGM) for people with Type 1 and insulin-dependent Type 2 diabetes. Unlike current CGM devices from Abbott, Dexcom, and Medtronic — which measure glucose in interstitial fluid with a 15-20 minute lag and require replacement every 7-15 days — Glucotrack's device places a sensor lead directly into a blood vessel to measure blood glucose with no lag. The device is designed to last at least 3 years, far longer than any commercially available competitor. The device is fully implantable with no external wearable component. Glucotrack completed its first-in-human study in early 2025 on 8 patients in Brazil, meeting safety and performance endpoints. The next major milestone is an FDA Investigational Device Exemption filing in Q2 2026, with a U.S. clinical trial targeted for the second half of 2026. Glucotrack is pursuing a De Novo 510(k) regulatory pathway, which is less burdensome than the PMA process. The company has not yet defined a go-to-market strategy, but once commercialized, revenue would come from the implant itself and periodic replacement sensors. Reimbursement from Medicare and private insurers will be critical to commercial viability. Glucotrack has 15 employees, with leadership drawing heavily from Dexcom and Medtronic.